Within internal medicine, our scientists are focused on discovering and developing therapies for metabolic disease, cardiovascular risk, diabetes, cachexia, non-alcoholic steatohepatitis (NASH) and fatty liver disease.
In recent decades there have been remarkable reductions in death from cardiovascular diseases, largely due to a decreased prevalence of smoking and modern science that has led to effective therapies for hypertension and high cholesterol.1 Even so, cardiovascular diseases (CVD) remain the number one cause of death worldwide.2
We believe that a comprehensive programme is needed to address the collection of diseases of the cardiovascular system, as well as their root causes, including obesity and metabolic disease.
For more than 50 years, Pfizer has led the way in redefining the management of cardiovascular risk by bringing much-needed treatments to patients.
Today, Pfizer is focused on investigating potential therapies that treat both the metabolic abnormalities that increase the likelihood of cardiovascular disease, and the heart itself. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients.
Our early discovery efforts focus on emerging areas of cardiovascular research such as control of eating disorders, type 2 diabetes/muscle uptake of glucose and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Research is improving our understanding of osteoarthritis, but it’s still not clear exactly what causes it.
'Breakthrough Nation II' provides our latest thinking for how industry and government can work better together.
At Pfizer, we know that patients and caregivers are the experts in their conditions.
NCBI. Decline in Cardiovascular Mortality: Possible Causes and Implications Jan 2017.
WHO. Cardiovascular diseases (CVDs) June 2021.